Salute e Benessere

Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular…

For those in the early stages of the disease (Ann Arbor stages I or II), treatment may involve radiation therapy alone or in combination with chemotherapy. Patients with advanced follicular lymphoma are typically treated initially with a combination of chemotherapy and anti-CD20 antibodies, a method known as chemoimmunotherapy. The most commonly used antibodies are RITUXAN (rituximab) and GAZYVA (obinutuzumab), which specifically target tumor cells associated with follicular lymphoma. In older…
PR Newswire
16/09/2024

Galapagos receives transparency notification from EcoR1 Capital

Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.Pursuant to Belgian transparency legislation 1, Galapagos received a transparency notification on 13 September 2024 on behalf of Mr. Oleg Nodelman and EcoR1 Capital LLC, who notified that EcoR1 Capital LLC holds 6,713,553 of Galapagos' voting rights, consisting of 839,388 ordinary shares and 5,874,165 American...
Nasdaq GlobeNewswire
16/09/2024

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,537,214,304 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
16/09/2024

Lab Automation Market to Reach $11.31 Billion by 2031, Driven by Rising…

Download FREE PDF Brochure Of Lab Automation Market - https://www.meticulousresearch.com/pressrelease/967/lab-automation-market-2031 Download FREE PDF Brochure Of Lab Automation Market - https://www.meticulousresearch.com/pressrelease/967/lab-automation-market-2031 Rising pharmaceutical and biotech R&D expenditures, the increasing demand for automated laboratories and instruments, the high prevalence of chronic and infectious diseases, and initiatives supporting life sciences...
PR Newswire
16/09/2024

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options. WGc-043, the world's...
PR Newswire
16/09/2024

Immunovia presents data from model development study at 2024 AACR Advances in…

The conference is being hosted by the American Association for Cancer Research (AACR) in Boston, Massachusetts. This special conference brings together leading pancreatic cancer researchers, physicians, and patient advocates to share innovative approaches for diagnosing and treating pancreatic cancer. The conference is being hosted by the American Association for Cancer Research (AACR) inBoston, Massachusetts. This special conference brings together leading pancreatic cancer researchers,...
PR Newswire
16/09/2024

TraceLink Co-Founder and SVP of Supply Network Products Lucy Deus Named…

As global supply chains face increased complexity, challenges, and digitalization opportunities, Lucy Deus is driving transformational change at TraceLink for the benefit of its customers and patients globally. As a critical leadership voice, Deus has been instrumental in bringing the voice of the customer and supply chain experience to help shape its unique Opus platform as a critical supply chain digitalization capability. This collaboration has ensured that the platform is optimized to meet…
PR Newswire
16/09/2024

Epitomee Medical Announces FDA Clearance of its Capsule, Weight Management…

The Epitomee® Capsule represents an innovative prescription option in weight management solutions, offering a drug-free alternative that differs from injectable treatments. With FDA clearance extending to adults with a BMI starting at 25, Epitomee® Capsule is accessible to a broader range of patients looking for tolerable and easy to use weight management solutions. The Epitomee® device is encased in a standard size, self-administered ingestible capsule. Once the Epitomee® Capsule is swallowed…
PR Newswire
16/09/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 16092024_trading_in_shares_KV
Nasdaq GlobeNewswire
16/09/2024

Lipid Nanoparticles Market to Reach USD 350.5M by 2029 | MarketsandMarkets™

Browse in-depth TOC on "Lipid Nanoparticles Market" Browse in-depth TOC on "Lipid Nanoparticles Market" 398 - Tables53 - Figures316 - Pages Factors Influencing Market Trends The expansion of the lipid nanoparticles market is driven by increasing research and development efforts to create lipid nanoparticle-based drugs. However, stringent regulatory requirements may impede growth. Product Segment Insights The market is segmented by product into ionizable...
PR Newswire
16/09/2024

Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD…

The report highlights key market drivers, including the growing demand for early fetal detection, advancements in next-generation sequencing (NGS), and the increased adoption of safer prenatal testing methods. It also addresses critical market restraints such as high costs, regulatory hurdles, and limited insurance coverage, providing a balanced view of current market dynamics. The report highlights key market drivers, including the growing demand for early fetal detection, advancements in...
PR Newswire
16/09/2024

Trading by management and close relations of management

Please read the full announcement in PDF Attachment 2024_37_Trading_By_Management
Nasdaq GlobeNewswire
16/09/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 16 September 2024– On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under…
Nasdaq GlobeNewswire
16/09/2024

Lexogen launches LUTHOR HD Pool and a dedicated LUTHOR single cell dispenser…

Complementing this innovation is the LUTHOR single cell dispenser, a compact and user-friendly instrument designed to enhance the efficiency of single-cell RNA sequencing workflows. Capable of gently dispensing cells one at a time, this device ensures precise isolation of individual cells, reducing the risk of doublets and debris contamination. With a dispensing accuracy that outperforms manual pipetting and compatibility with both fresh and fixed cells, the LUTHOR single cell dispenser offers…
PR Newswire
16/09/2024

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

Speaking on this pivotal step forward, Nandini Piramal, Chairperson, Piramal Pharma Limited, said, "Sustainability is at the heart of our business strategy, and the approval from SBTi reinforces our ongoing commitment to reducing our GHG emissions and aligning with global climate action goals. This is a critical step in our broader sustainability roadmap, and we are committed to doing our part in driving meaningful environmental change across the pharmaceutical industry. To further…
PR Newswire
16/09/2024

Final results from CABINET Phase III trial reinforce efficacy benefits of…

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx ®(cabozantinib) versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) 1 ,2 Data presented at ESMO 2024 and published in New England Journal of Medicine Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines AgencyLimited approved treatment...
Nasdaq GlobeNewswire
16/09/2024

Buyback of Class B shares in Essity during week 37, 2024

The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
16/09/2024

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's…

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies The THERICEL project is intended to establish the viability of using proprietary Theriva's A549 suspension cell platform for the clinical manufacture of adenoviral and AAV therapies. Suspension cell manufacture is expected to dramatically increase efficiency and decrease the cost of manufacturing...
Nasdaq GlobeNewswire
16/09/2024

Virbac: erratum short Press release Capital reduction_September 13, 2024

This press release rectifies the version of the press release issued by Virbac on September 13, 2024 at 5:45 pm in order to correct a typing error in the amount of Virbac's new share capital.The share capital of Virbac amounts now to €10,488,325 and not €10,448,325 as announced.Focusing on animal health, from the beginningAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our...
Nasdaq GlobeNewswire
16/09/2024

PhytoHealth Corporation announced a new clinical study results published at 2024…

Results showed that patients who received PG2 in addition to CCRT experienced significantly longer overall survival compared to those who received CCRT alone. Furthermore, the combination therapy resulted in a higher tumor objective response rate. The study also found that PG2 helped strengthen the immune system by modulating the tumor immune microenvironment (TIME) and enhancing the suppression of tumor growth. Results showed that patients who received PG2 in addition to CCRT experienced...
PR Newswire
16/09/2024

Evaxion reports convincing one-year data from phase 2 trial on AI-designed…

11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate15 out of the 16 patients had a reduction of their tumors (target lesions)79% of EVX-01's vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response (p=0.00013)EVX-01 as a novel potential melanoma treatment...
Nasdaq GlobeNewswire
16/09/2024

Boehringer's nerandomilast meets primary endpoint in pivotal phase-III…

Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] at week 52 versus placebo. The FIBRONEER™-IPF trial is the largest trial in idiopathic pulmonary fibrosis (IPF) conducted to date. Patients were recruited in over 330 sites and in over 30 countries. 1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025.Boehringer...
Nasdaq GlobeNewswire
16/09/2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose…

TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on various solid cancersData from the first-in-human Phase 1 dose escalation trial demonstrate initial anti-tumor activity and a manageable tolerability profile for TCER® IMA401 monotherapy; patient population includes 35 heavily pre-treated patients across 16 different solid tumor types; dose...
Nasdaq GlobeNewswire
16/09/2024

Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of…

Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease 1 Results remain consistent across secondary endpoints, including distant disease-free survival, with a trend for improved overall survival* 1 Safety is in line with previously reported results with generally low-grade symptomatic adverse events, reinforcing well-tolerated profile 1 People...
Nasdaq GlobeNewswire
16/09/2024
Altri  Comunicati